Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 9, 1156
eCollection

Antimicrobial Medicines Consumption in Eastern Europeand Central Asia - An Updated Cross-National Study and Assessment of QuantitativeMetrics for Policy Action

Affiliations

Antimicrobial Medicines Consumption in Eastern Europeand Central Asia - An Updated Cross-National Study and Assessment of QuantitativeMetrics for Policy Action

Jane Robertson et al. Front Pharmacol.

Abstract

Introduction: Surveillance of antimicrobial medicines consumption is central to improving their use and reducing resistance rates. There are few published data on antibiotic consumption in Eastern Europe and Central Asia. To address this, 18 non-European Union (EU) countries and territories contribute to the WHO Regional Office for Europe (WHO Europe) Antimicrobial Medicines Consumption (AMC) Network. Objectives: (i) Analyze 2015 consumption of J01 class antibacterials for systemic use from 16 AMC Network members; (ii) compare results with 2011 data and 2015 ESAC-Net estimates; (iii) assess consumption against suggested indicators; (iv) evaluate the impact of planned changes to defined daily doses (DDDs) in 2019 for some commonly used antibiotics; and (v) consider the utility of quantitative metrics of consumption for policy action. Methods: Analysis methods are similar to ESAC-Net for EU countries. The Anatomical Therapeutic Chemical (ATC) classification and DDD methodology were used to calculate total consumption (DDD/1000 inhabitants/day [DID]), relative use measures (percentages), extent of use of WHO Watch and Reserve group antibiotics and impact of DDD changes. Findings: Total J01 consumption in 2015 ranged 8.0-41.5 DID (mean 21.2 DID), generally lower than in 2011 (6.4-42.3 DID, mean 23.6 DID). Beta-lactam penicillins, cephalosporins, and quinolones represented 16.2-56.6, 9.4-28.8, and 7.5-24.6% of total J01 consumption, respectively. Third-generation cephalosporins comprised up to 90% of total cephalosporin consumption in some countries. Consumption of WHO Reserve antibiotics was very low; Watch antibiotics comprised 17.3-49.5% of total consumption (mean 30.9%). Variability was similar to 2015 ESAC-Net data (11.7-38.3 DID; mean 22.6 DID). DDD changes in 2019 impact both total and relative consumption estimates: total DIDs reduced on average by 12.0% (7.3-35.5 DID), mostly due to reduced total DDDs for commonly used penicillins; impact on rankings and relative use estimates were modest. Discussion: Quantitative metrics of antibiotic consumption have value. Improvements over time reflect national activities, however, changes in total volumes may conceal shifts to less desirable choices. Relative use measures targeting antibiotics of concern may be more informative. Some, including WHO Watch and Reserve classifications, lend themselves to prescribing targets supported by guidelines and treatment protocols.

Keywords: Central Asia; Eastern Europe; antibiotic utilization; antimicrobial medicines consumption; cross-national comparative study; national surveillance networks; quality indicators.

Figures

FIGURE 1
FIGURE 1
Total consumption of J01 antibacterials by pharmacological subgroup in 15 countries and Kosovo, 2015. DDD, Defined Daily Dose; Kosovo [in accordance with United Nations Security Council resolution 1244 (1999)]; #Kazakhstan: commercial data source provides coverage of around 80–85% of hospital and community sales.
FIGURE 2
FIGURE 2
Consumption of cephalosporins and quinolones as a proportion of the total consumption of J01 antibacterials, 2015. Kosovo [in accordance with United Nations Security Council resolution 1244 (1999)].
FIGURE 3
FIGURE 3
Relative consumption of cephalosporins by generation of agents, 2015. Kosovo [in accordance with United Nations Security Council resolution 1244 (1999)].
FIGURE 4
FIGURE 4
Consumption of “Watch” group of antibiotics classes as a proportion of total consumption of antibacterials. Watch group: Quinolones (J01MA and J01MB); 3rd generation cephalosporins (J01DD); macrolides (J01FA); glycopeptides (J01XA and A07AA09); antipseudomonal penicillins with beta-lactamase inhibitor (J01CR03 and J01CR05); carbapenems (J01DH); and faropenem (J01DI03). Kosovo [in accordance with United Nations Security Council resolution 1244 (1999)].

Similar articles

See all similar articles

Cited by 2 PubMed Central articles

References

    1. Abilova V., Kurdi A., Godman B. (2018). Ongoing initiatives in Azerbaijan to improve the use of antibiotics; findings and implications. Expert Rev. Anti Infect. Ther. 16 77–84. 10.1080/14787210.2018.1417835 - DOI - PubMed
    1. Access to Medicines Foundation (2018). Antimicrobial Resistance Benchmark 2018. Available at: https://amrbenchmark.org/wp-content/uploads/2018/03/Antimicrobial-Resistance-Benchmark-2018.pdf [accessed March 10 2018].
    1. Adriaenssens N., Coenen S., Tonkin-Crine S., Verheij T. J., Little P., Goossens H. (2011). European surveillance of antimicrobial consumption (ESAC): disease-specific quality indicators for outpatient antibiotic prescribing. BMJ Q. Safety 20 764–767. 10.1136/bmjqs.2010.049049 - DOI - PubMed
    1. Bojanic L., Markovic-Pekovic V., Skrbic R., Stojakovic N., Ethermanovic M., Bojanic J., et al. (2018). Recent initiatives in the republic of srpska to enhance appropriate use of antibiotics in ambulatory care; their influence and implications. Front. Pharmacol. 9:442. 10.3389/fphar.2018.00442 - DOI - PMC - PubMed
    1. Bruyndonckx R., Hens N., Aerts M., Goossens H., Molenberghs G., Coenen S. (2014). Measuring trends of outpatient antibiotic use in Europe: jointly modelling longitudinal data in defined daily doses and packages. J. Antimicrob. Chemother. 69 1981–1986. 10.1093/jac/dku063 - DOI - PubMed
Feedback